| (Values in U.S. Thousands) | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 |
| Sales | 21,750 | 18,680 | 15,000 | 15,140 | 11,820 |
| Sales Growth | +16.43% | +24.53% | -0.92% | +28.09% | +24.03% |
| Net Income | -21,900 | -30,430 | -23,500 | -86,500 | -23,020 |
| Net Income Growth | +28.03% | -29.49% | +72.83% | -275.76% | +31.85% |
Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.
Fiscal Year End Date: 12/31